https://www.statcounter.com/counter/counter.js
Web Analytics
Home » Posts tagged with » multiple sclerosis
Cyxone achieves safety, tolerability goals in T20K MS clinical trial

Cyxone achieves safety, tolerability goals in T20K MS clinical trial

T20K MS clinical trial : Swedish biotech company Cyxone said that a phase 1 clinical trial for its drug candidate T20K for multiple sclerosis (MS) has confirmed its safety and tolerability in humans. Cyxone said that there were no serious adverse events in the early-stage infusion study. As the next step in its development program, […]

Janssen’s Ponesimod OPTIMUM trial in MS meets primary endpoint

Ponesimod OPTIMUM trial results :  Johnson & Johnson’s Janssen Pharmaceutical said that the phase 3 OPTIMUM clinical trial evaluating ponesimod yielded positive results compared to Aubagio (teriflunomide) in adults having relapsing multiple sclerosis (MS). The OPTIMUM clinical trial, which enrolled 1,133 participants, assessed the efficacy and safety of the selective sphingosine-1-phosphate receptor 1 (S1P1) modulator […]

Continue reading …
Convelo, Genentech to collaborate on remyelination drugs for MS

US biotech company Convelo Therapeutics has signed an exclusive worldwide collaboration with Roche subsidiary Genentech to fast track discovery and development of novel remyelination drugs for the treatment of multiple sclerosis (MS) and other neurological disorders. Convelo Therapeutics, which is headquartered in Cleveraland, Ohio, is engaged in discovering a new class of drugs that regenerate the […]

Continue reading …
Novartis’ Mayzent approved by FDA for treatment of relapsing forms of MS

Mayzent FDA approval : The US Food and Drug Administration (FDA) has approved Swiss pharma company Novartis’ Mayzent (siponimod) for the treatment of relapsing forms of multiple sclerosis (MS) in adults. Mayzent FDA approval The latest FDA approved Novartis MS drug can now be used for the treatment of secondary progressive multiple sclerosis (SPMS) with […]

Continue reading …
Novartis bags Gilenya EC approval for multiple sclerosis in young patients

Gilenya EC approval : The European Commission (EC) has expanded the approval of Novartis multiple sclerosis drug Gilenya (fingolimod) to include the treatment of both children and adolescents, in the age group 10-17 years. Expanded Gilenya EC approval The expanded Gilenya EC approval is for the treatment of relapsing-remitting forms of multiple sclerosis (RRMS). Novartis already […]

Continue reading …
Genentech MS drug Ocrevus approved by FDA for multiple sclerosis treatment

Roche Group’s subsidiary Genentech has secured the US FDA approval for its multiple sclerosis drug, Ocrevus (ocrelizumab) for treating both relapsing and primary progressive variants of the chronic disease through intravenous infusion. The FDA approval has made the Genentech MS drug Ocrevus as the first and only therapy available for the two forms of multiple […]

Continue reading …